Korean Drug Co. Ltd (014570) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Korean Drug Co. Ltd KRW 9,585, price KRW 3,195, upside +200.0%, quality 70 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Korean Drug Co. Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 3,120 KRW – 10,389 KRW · fair‑value band 7,284 KRW – 11,886 KRW · the 3,195 KRW price screens below the 9,585 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Korean Drug Co. in your weekly email
Every Wednesday you see whether Korean Drug Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Korean Drug Co., Ltd. manufactures and sells medicines for treating various diseases in South Korea.
Show more
Korean Drug Co., Ltd. manufactures and sells medicines for treating various diseases in South Korea. The company offers Medicines for urinary tract disease, digestive system, circulatory system, psychonervous system, central nervous system, respiratory system, and skin and subcutaneous system; and antivirals, antibiotics, antifungals, antipyretic, analgesis, anti-inflammatory, and other products. Korean Drug Co., Ltd. was founded in 1980 and is headquartered in Seoul, South Korea.
Stock analysis
Korean Drug Co. Ltd (014570) currently trades at 3,195 KRW, while our model-based Fair Value estimate is 9,585 KRW, implying the stock looks roughly 66.7% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 12,730 KRW per share, and 22 of the 22 models we run sit above the 3,195 KRW price.
Bear case: the Earnings-Based group reads lowest at 4,377 KRW, and 0 of the 22 models stay below the price. Evidence for this calculation is low.
Scenario range: 7,284 KRW (bear) to 11,886 KRW (bull), the price of 3,195 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 70/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Korean Drug Co. Ltd reported revenue of 62.5B KRW in FY2025 versus 74.5B KRW in FY2021, a compound −4.3%/yr. Reported net income was 6.5B KRW in FY2025, compounding −7.9%/yr from FY2021.
Key figures
Market cap 34.6B KRW (≈ $24.2M) · P/S ratio 0.59 · Dividend yield 5.6% · Net margin 10.4% · Return on equity 8.7% · Return on assets (EBIT) 13.1% · Operating margin 8.8% · Revenue (TTM) 62.8B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 51 out of 100 (low confidence).
What moves the price
The share trades about 27% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −2% fair-value upside, at 200%, 014570 screens cheaper than that median.
Fair Value models
Bear 7,284 KRWFair Value 9,585 KRWBull 11,886 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−14.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.3%
Start year 2020 (pandemic). Over 10 years: +2.8% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+3.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year−2.3%
Dividend (yield on the price)5.6%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−2% vs 3%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 11%
Start year 2020 (pandemic)
Growth Forecast
Little optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
less than -40 %
Yearly growth needed for the next five years to justify today's price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 74 stocks
Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score70 · Above median
Fair Value upside+200% · Top 25%
Profitability
Return on equity (TTM)9% · Below median
Return on assets5% · Below median
Net margin (TTM)11% · Below median
Operating margin (TTM)9% · Below median
Growth and dividend
Revenue growth2% · Below median
Dividend yield (TTM)5.6% · Top 25%
Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Korean Drug Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/014570
Frequently asked questions
Is Korean Drug Co. Ltd (014570) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 9,585 KRW versus a price of 3,195 KRW, about +200% upside (undervalued).
What is the fair value of 014570?
Our model-based fair value for Korean Drug Co. Ltd is 9,585 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 3,195 KRW.
What is the quality score of 014570?
Korean Drug Co. Ltd has a Quality Score of 70/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Korean Drug Co. Ltd (014570)?
Our model-based price target is the fair value of 9,585 KRW (as of Sep 24, 2026) from 22 valuation models. Cautious scenario 7,284 KRW, optimistic scenario 11,886 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Korean Drug Co. Ltd stock forecast for 2026?
Our models put fair value at 9,585 KRW, about +200% upside versus a price of 3,195 KRW (undervalued). Cautious scenario 7,284 KRW, optimistic scenario 11,886 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Korean Drug Co. Ltd (014570)?
Korean Drug Co. Ltd reported trailing-twelve-month revenue of about 62.8B KRW (latest available figure, as of Sep 24, 2026).
Does Korean Drug Co. Ltd pay a dividend?
Korean Drug Co. Ltd currently shows a dividend yield of about 5.63% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Korean Drug Co. Ltd (014570)?
For today's price to be fair in a discounted-cash-flow model, Korean Drug Co. Ltd would have to grow free cash flow by less than minus 40 % per year for five years (discount rate 8.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -1.3 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 014570 use?
Our models discount Korean Drug Co. Ltd at 8.9 %: a base by market capitalisation (nano), damped by beta 0.22, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Korean Drug Co. Ltd that is less than minus 40 % per year a year over ten years, using the same discount rate (8.9 %) and the same formula as our fair value.
How much growth has Korean Drug Co. Ltd (014570) delivered so far?
Over the past 5 years revenue at Korean Drug Co. Ltd grew -1.3 % a year. The price currently implies less than minus 40 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Korean Drug Co. Ltd (014570) growing?
The median revenue growth in the sector is +1.8 % a year. That is the yardstick for the growth priced into Korean Drug Co. Ltd (less than minus 40 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Korean Drug Co. Ltd (014570)?
The free-cash-flow yield on the price is 36.53 %: that much free cash flow Korean Drug Co. Ltd produces per unit of market value. When it exceeds the discount rate of our models (8.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Korean Drug Co. Ltd (014570)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Korean Drug Co. Ltd it is 9,585 KRW per share (as of Sep 24, 2026), against a price of 3,195 KRW. It is the blended result of 22 valuation models (cash flow, earnings, asset, dividend).
Is Korean Drug Co. Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 014570 trades below its calculated fair value: price 3,195 KRW, fair value 9,585 KRW, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 014570?
No. The price is what the market pays today (3,195 KRW); the fair value is what the company's own numbers justify (9,585 KRW). For Korean Drug Co. Ltd the two are 6,390 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Korean Drug Co. Ltd worth?
The market values Korean Drug Co. Ltd at about 34.6B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 3,195 KRW; our models calculate a fair value of 9,585 KRW per share.
What do the bullish and bearish scenarios say about 014570?
Our models span a range for Korean Drug Co. Ltd: cautious scenario 7,284 KRW, base 9,585 KRW, optimistic 11,886 KRW per share (as of Sep 24, 2026, price 3,195 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Korean Drug Co. Ltd (014570)?
Balance-sheet figures for Korean Drug Co. Ltd (as of Sep 24, 2026): return on equity 8.7%. They feed the Quality Score of 70/100, which measures business quality independently of the share price.
How far is 014570 from its 52-week high?
Korean Drug Co. Ltd trades at 3,195 KRW, about 27% below its 52-week high of 4,391 KRW and 2% above the low of 3,120 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 9,585 KRW is for.
Which stocks are comparable to Korean Drug Co. Ltd?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Korean Drug Co. Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 3,195 KRW, calculated fair value 9,585 KRW (+200%), Quality Score 70/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 014570 calculated?
We run Korean Drug Co. Ltd through 22 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 9,585 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Korean Drug Co. Ltd currently trades 200 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Korean Drug Co. Ltd (014570)?
The closing price on Sep 23, 2026 was 3,195 KRW. Our model-based fair value is 9,585 KRW, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Korean Drug Co. Ltd right now?
The rarer combination: high quality (70/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case (7,284 KRW). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Korean Drug Co. Ltd
How large is the market capitalisation of Korean Drug Co. Ltd (014570)?
The market capitalisation of Korean Drug Co. Ltd is 34.6B KRW (≈ $24.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Korean Drug Co. Ltd (014570)?
The price-to-sales ratio of Korean Drug Co. Ltd is 0.59 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Korean Drug Co. Ltd (014570)?
The dividend yield of Korean Drug Co. Ltd is 5.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Korean Drug Co. Ltd (014570)?
The net margin of Korean Drug Co. Ltd is 10.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Korean Drug Co. Ltd (014570)?
The return on equity (ROE) of Korean Drug Co. Ltd is 8.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Korean Drug Co. Ltd (014570)?
On an EBIT basis the return on assets of Korean Drug Co. Ltd is 13.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Korean Drug Co. Ltd (014570)?
The operating margin of Korean Drug Co. Ltd is 8.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Korean Drug Co. Ltd (014570)?
Revenue at Korean Drug Co. Ltd is growing +1.9% versus a year earlier (3y avg −7.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Korean Drug Co. Ltd (014570)?
Earnings per share at Korean Drug Co. Ltd are growing +47.2% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Korean Drug Co. Ltd in the live analysis
One click puts Korean Drug Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
